Le Thuy

Researchers are evaluating the DynamX Coronary Bioadaptor System in patients with coronary artery disease caused by new native coronary artery lesions. This registry aims to confirm the safety, effectiveness, and performance of this device in a real-world patient population. The study focuses on patients who require percutaneous coronary intervention (PCI) with stent implantation. All participants will receive at least one DynamX Novolimus-eluting Coronary Bioadaptor implant following the product's Instructions for Use. The treatment is provided in a commercial setting as part of routine clinical care. This registry collects additional data on the device's performance and safety over time in patients undergoing this procedure. Participants will be monitored for at least 12 months to assess device-oriented clinical outcomes. Researchers will collect data on safety and effectiveness during this period. Patient involvement includes providing informed consent and complying with study procedures. The total duration of participation is based on the 12-month follow-up for clinical endpoints.